Inyesprin

D,L-lysine acetylsalicylate, the active ingredient in Inyesprin, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an injectable for intramuscular and intravenous use. It is employed to relieve pain, reduce fever, control inflammation and inhibit platelet aggregation in adult patients when a rapid systemic effect is required.

GNH USA supplies Inyesprin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inyesprin, an NSAID that blocks prostaglandin synthesis, is used in several clinical situations: - Pain relief: provides analgesia by decreasing peripheral pain mediators. - Fever reduction: lowers elevated body temperature through central thermoregulatory inhibition. - Inflammation control: diminishes swelling and redness by limiting inflammatory prostaglandins. - Prevention of platelet aggregation: reduces thromboxane A2 formation, helping to prevent clot formation in at‑risk patients.

Common Side Effects: - Gastrointestinal discomfort or dyspepsia. - Nausea or vomiting. - Headache. - Dizziness. - Injection‑site pain or erythema. - Mild transient rash.

Serious or Rare Side Effects: - Gastrointestinal bleeding or ulceration. - Severe hypersensitivity reactions, including anaphylaxis. - Renal impairment or acute kidney injury. - Thrombocytopenia or abnormal bleeding. - Hepatotoxicity. - Severe skin reactions such as Stevens‑Johnson syndrome.

Before using Inyesprin, consider the following safety measures: - Assess bleeding risk: avoid in patients with active ulcers or recent surgery. - Monitor renal function: adjust use in those with impaired kidney function. - Use cautiously in asthma: NSAIDs may trigger bronchospasm. - Avoid in known hypersensitivity to salicylates or related compounds. - Employ the lowest effective dose for the shortest duration needed. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Inyesprin may interact with several medicines: Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other NSAIDs or aspirin: additive gastrointestinal toxicity. - Selective serotonin reuptake inhibitors (SSRIs): heightened hemorrhage potential. Moderate Interactions (Monitor Closely):\n- ACE inhibitors or diuretics: possible reduction in renal perfusion. - Methotrexate: decreased clearance leading to toxicity.